Swiss Software Stock News

UBS Group (SWX:UBSG) is in focus after recent share price weakness, with the stock showing negative returns over the past month and past 3 months, prompting investors to reassess its long term performance profile. See our latest analysis for UBS Group. At a share price of CHF29.51, UBS Group’s recent 30 day share price return of 11.91% and year to date share price return of 22.69% contrast with a 1 year total shareholder return of 8.57%, and the stronger 3 year and 5 year total shareholder...

Accelleron Industries (SWX:ACLN) is back in focus after reporting robust 2025 revenue and earnings, pairing a higher dividend with a CHF 100 million buyback plan and guidance for continued profitable growth into 2026. See our latest analysis for Accelleron Industries. The strong 2025 results, higher dividend, and CHF 100 million buyback have coincided with a sharp shift in sentiment. A 1-day share price return of 11.76% has helped lift the year-to-date share price return to 16.96%, while the...

Comet Holding (SWX:COTN) is in focus after its latest full year earnings showed higher sales alongside weaker profitability, paired with a proposed dividend cut and mixed guidance that coincided with a sharp share price drop. See our latest analysis for Comet Holding. The earnings miss, dividend cut proposal and reference to valuation compression have quickly fed into sentiment. The share price at CHF249.4 now carries a 7 day share price return of 12.12% and a 30 day share price return of...

What triggered the latest move in PolyPeptide Group? PolyPeptide Group (SWX:PPGN) released full-year 2025 results in line with expectations and paired them with 2026 guidance that indicates higher revenue and margins, along with an upcoming CFO change. See our latest analysis for PolyPeptide Group. The upbeat 2025 results and 2026 guidance have come alongside a sharp shift in sentiment, with an 8.78% 1 day share price return and a year to date share price return of 11.04%. The 1 year total...

Novartis (SWX:NOVN) is back on investor radars after recent share price moves, with the stock showing mixed short term performance but stronger returns over the past 3 months and year. See our latest analysis for Novartis. The recent 1 week and 1 day share price declines sit against a stronger 90 day share price return of 14.5% and a 1 year total shareholder return of 28.5%. This suggests momentum has been building over a longer horizon despite near term softness. If Novartis has caught your...

BKW (SWX:BKW) has put out its FY 2025 numbers with first half revenue of CHF 2.1b and basic EPS of CHF 3.54. This sets the tone for a year in which trailing twelve month revenue sits at CHF 4.5b and EPS at CHF 6.77. Over the last few reporting periods, the company has seen revenue move from CHF 2.2b and EPS of CHF 6.62 in 1H 2024 to CHF 2.4b and EPS of CHF 5.18 in 2H 2024, before landing at the latest 1H 2025 figures. This leaves investors focused on how the compression in net profit margins...

Vetropack Holding (SWX:VETN) has just posted its FY 2025 numbers, with first half revenue at CHF 412.7 million and EPS of CHF 0.49, while trailing 12 month revenue sits at CHF 792.1 million and EPS at CHF 0.19 after a period marked by a CHF 17.1 million one off loss and a 0.5% net margin in the inputs. The company has seen reported revenue move from CHF 444.9 million in the first half of 2024 to CHF 412.7 million in the first half of 2025, with EPS shifting from CHF 0.47 to CHF 0.49 over the...

Geberit (SWX:GEBN) has wrapped up FY 2025 with fourth quarter revenue of CHF 715.4 million and Basic EPS of CHF 3.14, alongside trailing twelve month revenue of CHF 3.2 billion and EPS of CHF 18.15 that frame the full year earnings picture. Over recent periods, the company has seen quarterly revenue move from CHF 685.3 million in Q4 2024 to CHF 715.4 million in Q4 2025, while Basic EPS in those fourth quarters shifted from about CHF 2.93 to CHF 3.14. This gives investors a clear read on top...

Chocoladefabriken Lindt & Sprüngli (SWX:LISN) has wrapped up FY 2025 with second half revenue of CHF3.6b and basic EPS of CHF2,368.83, alongside net income of CHF538.3m, setting the tone for how investors will read the latest full year story. Over the past few periods, the company has seen revenue move from CHF3.3b in 2H 2024 to CHF3.6b in 2H 2025, while trailing twelve month basic EPS tracked at CHF3,163.95 and net income at CHF727.2m. This gives a clearer view of the earnings run rate...

Kardex Holding (SWX:KARN) has just posted its FY 2025 numbers with first half revenue of €415.7 million, basic EPS of €4.69 and net income of €36.2 million, while the trailing twelve months show revenue of €850.4 million, EPS of €5.39 and net income of €41.6 million. The company has seen revenue move from €369.7 million and EPS of €4.95 in 2024 H1 to €421.5 million and EPS of €5.50 in 2024 H2, setting up FY 2025 results against a backdrop of shifting profitability and mixed margin signals...

Huber+Suhner (SWX:HUBN) has just posted its FY 2025 first half results, logging revenue of CHF 445.9 million and basic EPS of CHF 1.97, compared with revenue of CHF 430.6 million and EPS of CHF 1.87 in the first half of FY 2024. Over the same period, trailing twelve month revenue has been in the range of CHF 864.1 million to CHF 909.2 million, while trailing EPS moved from CHF 3.87 to CHF 4.03. This provides investors with a relatively steady view of earnings power and a margin profile that...

Partners Group Holding (SWX:PGHN) has drawn fresh attention after reporting full year 2025 earnings and declaring an annual dividend of CHF 46.00 per share, with payment scheduled for late May 2026. See our latest analysis for Partners Group Holding. Even with the strong 2025 results and the CHF 46.00 dividend announcement, the share price has been under pressure, with a 30 day share price return of 18.15% and a 1 year total shareholder return of 34.06%. The 3 year total shareholder return of...

Avolta (SWX:AVOL) just wrapped up FY 2025 with second half revenue of CHF 7.2b and basic EPS of CHF 1.19, alongside full year net income excluding extra items of CHF 199m on trailing 12 month revenue of CHF 14.0b and EPS of CHF 1.39. The company has seen revenue move from CHF 7.3b and EPS of CHF 0.63 in the second half of 2024 to CHF 7.2b and EPS of CHF 1.19 in the second half of 2025, with trailing 12 month net profit margin at 1.4% versus 0.8% a year earlier. This sets up a results season...

Galenica’s FY 2025 Earnings Set Against Market Expectations Galenica (SWX:GALE) has reported its FY 2025 numbers with second half revenue of CHF 2.1b, basic EPS of CHF 1.90 and net income from continuing operations of CHF 94.4m, while trailing twelve month revenue stands at CHF 4.1b with EPS of CHF 3.67. The company has seen revenue move from CHF 2.0b in the first half of 2025 to CHF 2.1b in the second half and basic EPS shift from CHF 1.77 to CHF 1.90 over the same period, giving investors a...

Roche Holding (SWX:ROG) is back in focus for investors after recent trading pressure, with the share price down about 9% over the past month but roughly flat over the past 3 months. See our latest analysis for Roche Holding. At the latest share price of CHF318.2, Roche Holding is under short term pressure with a 1 week share price return of a 9.47% decline. However, its 1 year total shareholder return of 11.77% and 3 year total shareholder return of 35.03% indicate that performance has been...

If you are wondering whether UBS Group is fairly priced or offering value right now, looking closely at its current valuation can help you decide how it might fit into your portfolio. The share price closed at CHF 30.13, with returns of 2.8% decline over 7 days, 11.4% decline over 30 days, a 21.1% decline year to date, a 10.8% gain over 1 year, and a very large gain over 5 years. Recent news around UBS Group has focused on its role as a major Swiss-based global bank and wealth manager...

Sensirion Holding (SWX:SENS) has reported fresh FY 2025 numbers, with first half revenue at CHF 184.547 million and basic EPS of CHF 0.67, while trailing twelve month revenue stands at CHF 333.076 million and basic EPS at CHF 1.126105. The company has seen revenue move from CHF 127.972 million with basic EPS of CHF 2.31 in the first half of 2024 to CHF 148.529 million with basic EPS of CHF 0.45638 in the second half of 2024. This has set up the current CHF 184.547 million revenue and CHF 0.67...

Cosmo Pharmaceuticals (SWX:COPN) has just released its full year 2025 results, highlighting higher recurring revenues, a proposed €2.10 dividend per share, and management’s outlook for recurring revenue and EBITDA growth in 2026. See our latest analysis for Cosmo Pharmaceuticals. That earnings release came after a sharp pullback, with a 1 day share price return of a 5.25% decline and a 30 day share price return of a 19.74% decline. However, the 1 year total shareholder return of 82.16% still...

Partners Group Holding (SWX:PGHN) opened FY 2025 with first half revenue of CHF 1.2b and basic EPS of CHF 22.24, setting the tone for another data rich year of results. The company has seen revenue move from CHF 964.3m in the first half of 2024 to CHF 1.15b in the second half of 2024 and then to CHF 1.16b in the first half of 2025, while basic EPS shifted from CHF 19.52 to CHF 23.89 and then to CHF 22.24 over the same periods. With trailing net profit margins described at 49.2% compared with...

BKW (SWX:BKW) is back in focus after reporting a 40% drop in net profit tied to an extraordinary value adjustment on its German coal plant, while at the same time raising its dividend. See our latest analysis for BKW. At a share price of CHF149.0, BKW has a 90 day share price return of a 10.08% decline and a year to date share price return of a 13.87% decline. The 5 year total shareholder return of 54.09% points to stronger longer term compounding despite recent pressure, suggesting sentiment...

Flughafen Zürich (SWX:FHZN) has wrapped up FY 2025 with second half revenue of CHF 720.4 million, basic EPS of CHF 6.03 and net income of CHF 185.2 million, supported by trailing twelve month revenue of about CHF 1.4 billion and EPS of CHF 11.29. The company has seen revenue move from CHF 695.2 million in the second half of 2024 to CHF 720.4 million in the second half of 2025, while trailing twelve month EPS has shifted from CHF 10.64 to CHF 11.29. This gives investors a cleaner view on how...

What Implenia’s latest annual results mean for shareholders Implenia (SWX:IMPN) released its full year 2025 earnings, with sales of CHF 3,474.55 million and net income of CHF 83.64 million, both lower than the previous year, prompting fresh attention on the stock. See our latest analysis for Implenia. The earnings release appears to have reset expectations, with the share price at CHF73.50 and a 1 day share price return of 4.7% and a 90 day share price return of 7.9%. The 1 year total...

Avolta (SWX:AVOL) has drawn fresh attention after releasing full year 2025 results, reporting CHF 13,983 million in revenue and CHF 199 million in net income, along with higher earnings per share compared with the prior year. See our latest analysis for Avolta. The latest earnings release appears to have given Avolta’s share price a short term lift, with a 1 day share price return of 2.87% to CHF45.84. However, the 30 day share price return of a 7.21% decline suggests momentum has cooled,...

Roche Holding's oral SERD breast cancer candidate giredestrant did not meet the primary endpoint of progression free survival in the Phase III persevERA trial. The result affects expectations for one of Roche’s key late stage oncology assets and raises questions about the future shape of its pharma pipeline. Roche has indicated it will continue other giredestrant studies, while the market reassesses the commercial potential of the drug. For investors watching SWX:ROG, this clinical setback...